The New England journal of medicine
-
Comment Letter
BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
-
Editorial Comment
How to Fill the Void - Bone Cement in Hemiarthroplasty.
-
Randomized Controlled Trial Multicenter Study
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
The addition of pembrolizumab to neoadjuvant chemotherapy led to a significantly higher percentage of patients with early triple-negative breast cancer having a pathological complete response (defined as no invasive cancer in the breast and negative nodes) at definitive surgery in an earlier analysis of this phase 3 trial of neoadjuvant and adjuvant therapy. The primary results regarding event-free survival in this trial have not been reported. ⋯ In patients with early triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab after surgery, resulted in significantly longer event-free survival than neoadjuvant chemotherapy alone. (Funded by Merck Sharp and Dohme, a subsidiary of Merck; KEYNOTE-522 ClinicalTrials.gov number, NCT03036488.).